Company Filing History:
Years Active: 2020-2023
Title: The Innovative Contributions of Suzanne Bakewell
Introduction
Suzanne Bakewell is a notable inventor based in Tampa, FL (US). She has made significant strides in the field of cancer treatment through her innovative research and development. With a total of 2 patents to her name, her work is paving the way for new therapeutic options in oncology.
Latest Patents
One of her latest patents is focused on the use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer, specifically IT-139. This compound is an intravenously administered small molecule that has shown promising results in preclinical anti-tumor studies. IT-139 demonstrated activity against a wide range of tumor types, including those resistant to standard anti-cancer agents such as platinums, vinca alkaloids, taxanes, and anthracyclines. The mechanism of action for IT-139 targets the GRP78 pathway, which is crucial for cancer cell survival. By downregulating GRP78, IT-139 effectively removes resistance pathways, enhancing the efficacy of chemotherapy and immuno-oncology agents in cancer treatment.
Career Highlights
Suzanne Bakewell is currently associated with Bold Therapeutics, Inc., where she continues her groundbreaking work in cancer research. Her contributions to the field have been recognized for their potential to change the landscape of cancer therapy.
Collaborations
One of her notable coworkers is Jyothi Sethuraman, who collaborates with her on various projects aimed at advancing cancer treatment methodologies.
Conclusion
Suzanne Bakewell's innovative work and her patents are making a significant impact in the fight against cancer. Her research not only highlights the potential of new therapeutic agents but also underscores the importance of collaboration in scientific advancements.